Clinical Trials
38 trialsNCT04083235 2026-04-20
NAPOLI 3
Ipsen
Phase 3 Completed
NCT03785873 2026-02-13
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT03693677 2025-07-01
FUNGEMAX
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT05383352 2025-04-30
SIRACUSA
Ipsen
Phase 1 Completed
NCT03328884 2025-04-23
Phenomenal
MedSIR
Phase 2 Completed
NCT03861702 2025-04-18
Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT03468335 2025-04-17
PREDICT
AIO-Studien-gGmbH
Phase 3 Completed
NCT03088813 2025-02-19
RESILIENT
Ipsen
Phase 3 Completed
NCT02631733 2025-02-10
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT03719924 2025-01-08
OESIRI
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03837977 2024-12-30
NET02
The Christie NHS Foundation Trust
Phase 2 Completed
NCT02826486 2024-08-28
COMBAT
BioLineRx, Ltd.
Phase 2 Completed
NCT04728035 2024-07-26
Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02697058 2024-07-25
Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer
Servier
Phase 2 Completed
NCT03336216 2024-07-23
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT04727853 2024-07-10
Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT02231723 2023-11-18
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT03810742 2023-11-18
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
PharmaEngine
Phase 1 Completed
NCT02022644 2023-06-29
Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma
University of California, San Francisco
Phase 1 Completed
NCT03712397 2023-04-11
Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT03086616 2023-04-06
CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)
University of California, San Francisco
Phase 1 Completed
NCT04753216 2023-01-19
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Northwestern University
Phase 2 Completed
NCT04009876 2022-12-13
A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer
Fundación de investigación HM
Phase 2 Completed
NCT01926197 2022-10-28
Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
Stanford University
Phase 3 Completed
NCT03665441 2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3 Completed
NCT02551991 2022-10-10
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Ipsen
Phase 2 Completed
NCT03883919 2022-10-05
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Washington University School of Medicine
Phase 1 Completed
NCT03524508 2022-08-24
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
Asan Medical Center
Phase 2 Completed
NCT04088786 2022-05-06
Phase I Trial HIPEC With Nal-irinotecan
Stony Brook University
Phase 1 Completed
NCT05086822 2021-10-21
A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03207724 2020-12-30
OnFX
Cedars-Sinai Medical Center
Phase 1 Completed
NCT00062842 2020-03-04
Study of Irinotecan on a Weekly Schedule in Children
Baylor College of Medicine
Phase 1 Completed
NCT01770353 2019-11-27
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Ipsen
Phase 1 Completed
NCT00364143 2019-07-05
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors
Yakult Honsha Co., LTD
Phase 1 Completed
NCT02640365 2017-01-31
DOUBLIRI
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 1 Completed
NCT02884128 2016-08-30
A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors
PharmaEngine
Phase 1 Completed
NCT01494506 2016-06-17
NAPOLI-1
Merrimack Pharmaceuticals
Phase 3 Completed
NCT00734682 2015-01-07
A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
University of California, San Francisco
Phase 1 Completed